6 drug are dependent upon the tumour's sensitivity to the drug, its ability to develop resistant cell lines and whether, once the mass of the tumour has been killed, immunological mechanisms are effective in eliminating the remaining cells, such as is probably the case in Burkitt's tumour and choriocarcinoma. There are drugs whose action is directed against particular phases in the cell cycle; arrest in S and failure to enter S from G1 are well-recognized effects of compounds such as methotrexate or hydroxyurea; others, i.e. the vinca alkaloids, produce their lethal effects mainly in mitosis or G5. However, several drugs, i.e. the alkylating agents and corticosteroids, can exert a powerful lethal effect on non-dividing cells. The probability of being able to induce synchrony or partial synchrony in a tumour population in man is remote and, even if it were possible, it may well place the normal renewal tissues in far greater jeopardy than in the normal asynchronous state The alkylating agents continue to furnish the major proportion of the drugs in common use but later arrivals, notably vinblastine and procarbazine, are now of almost equal importance because of their lack of cross-resistance with the alkylating agents. Table 1 the use of maintenance therapy by vinblastine, procarbazine or cyclophosphamide did not produce longer remissions than those obtained from mustine as a single treatment. In a series of 60 patients treated by tretamine, usually over three days, the average duration of the remission was 13 weeks and, in a group of 29 patients treated by chlorambucil, using a maintenance regime, the average duration of remission was again 13 weeks. The author does not have access to a group started with mustine and maintained on chlorambucil to provide a precise comparison with Scott's series, but suggests that the value of maintenance treatment still requires confirmation.
Returning to the subject of cross-resistance as evidenced by the poor cyclophosphamide results in Table 1 , it is worth noting that the majority of patients in the vinblastine and procarbazine groups had had previous treatment with an alkylating agent but without impairing the response rate. Presumably this is due to differing modes of action of the drugs. For example, mustine appears to be effective throughout the cell cycle, whereas vinblastine's effect seems to be mainly limited to the period of mitosis.
Apart from the classes of agent already mentioned, there are other drugs such as actinomycin C, vincristine and the corticosteroids which are less constantly or less specifically effective in Hodgkin's disease.
It would be desirable to have a rational, scientifically based plan by which to determine the sequence of drugs to be used in late Hodgkin's disease as, after all, several different drugs will be used during the course of the disease in almost every case. There does not seem to be a great deal of information on the subject in the literature, perhaps because to permutate even three drugs will produce six different sequences, thus requiring a large supply of patients or pooling of resources from several centres to run a clinical trial. However, one recent paper, that by Ezdinli & Stutzman (1968) does show that the sequence mustine-vinblastine is superior to the sequence vinblastine-mustine. Most often the sequence used will be governed by the convenience to the patient, premiums being placed on those drugs which can be taken by mouth, are relatively safe and have minimal side-effects.
Carbone (Perry et al. 1967) 35 patients with early Hodgkin's disease confined to the neck were treated with a combination of regional X-ray treatment and mustine in standard dosage. These were compared with a closely similar group of 32 patients who had X-ray treatment alone. There was no significant difference between the two groups, the crude five-year survival rates being 54 % and 59 % respectively; as reported later by Halnan (1964) , at ten years the survival rates are 47 % and 46 % respectively. Miller (1966) discusses this work along with nine other published series in which radiation alone is compared with radiation and the use of an alkylating agent in Hodgkin's disease. He observes: 'The differing opinions are fairly well balanced between affirmative and negative views', but also points out that none of these series was randomized. Recently, Dr Thompson Hancock (1967) has published some preliminary results of a random trial of radiotherapy only, compared with a combination of radiotherapy and a single injection of mustine in Stage I and Stage II Hodgkin's disease. There were 97 patients in the trial at the time of reporting and the results appeared to be favouring the combination treatment, though the difference was not statistically significant.
As any one cytotoxic drug appears to be effective in little more than 60 % of cases and as the duration of response, where this can be demonstrated clinically, tends to be so short, it seems that a combination of three or more drugs administered over a relatively long period of time, similar to the combined treatment used by Carbone, should be employed to give the best prospect of demonstrating any effect in long-term survival rate. However, such a course of treatment is bound to be exhausting to the patient and is not without risk, so one is hesitant to set up such a trial where as many as 500% of the patients would be potential long-term survivors. Probably one should wait until combination regimes have been more fully assessed in patients in the later stages of the disease before using them in the early cases. One also hopes for the introduction of more potent drugs.
The position in Hodgkin's disease is also found in the other lymphomas with the proviso that, on the whole, chemotherapy tends to be rather less effective and there is often a less varied range of agents from which to choose. An outstanding exception, of course, is Burkitt's lymphoma in which chemotherapy is sometimes curative. Even in this condition, it is disappointing to find that in a recent symposium published in the International Journal of Cancer (1967) (1968) found cerebral involvement in 44% of patients with widespread melanoma who came to autopsy.
Chemotherapy and Irradiation
Malignant melanoma is generally held to be a radio-resistant disease though Lederman (1961) has pointed out that this is not true for all sites. The effects of irradiation are potentiated by certain cytotoxic drugs and this combination has been tested in melanoma by Dr Kenneth Newton using vinblastine intravenously. So far, more than half the patients, in a small series, have responded to a degree graded as excellent.
Regional Intra-arterial Chemotherapy Regional intra-arterial therapy was first described in 1950 by Klopp and his colleagues, who produced regression of epithelial tumours, hitherto not achieved by cytotoxic agents. From their original simple intra-arterial injection has stemmed a variety of technical modifications designed to permit higher regional dosage while reducing systemic toxicity from spill-over. 
